Baillie Gifford & Co. Has $278.69 Million Position in Exact Sciences Co. (NASDAQ:EXAS)

Baillie Gifford & Co. lowered its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 7.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,767,055 shares of the medical research company's stock after selling 299,275 shares during the quarter. Baillie Gifford & Co. owned 2.08% of Exact Sciences worth $278,687,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of EXAS. True Wealth Design LLC acquired a new stake in shares of Exact Sciences during the 4th quarter valued at $30,000. Wolff Wiese Magana LLC raised its position in shares of Exact Sciences by 459.5% during the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company's stock worth $31,000 after purchasing an additional 340 shares during the period. KB Financial Partners LLC purchased a new stake in shares of Exact Sciences during the second quarter valued at $32,000. BluePath Capital Management LLC acquired a new position in shares of Exact Sciences in the 3rd quarter valued at $33,000. Finally, Newbridge Financial Services Group Inc. purchased a new position in Exact Sciences in the 3rd quarter worth about $34,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXAS has been the subject of several recent analyst reports. Benchmark upgraded shares of Exact Sciences from a "hold" rating to a "buy" rating and set a $91.00 target price for the company in a report on Tuesday, January 2nd. Canaccord Genuity Group lowered their price objective on shares of Exact Sciences from $100.00 to $90.00 and set a "buy" rating on the stock in a research report on Thursday, February 22nd. Guggenheim began coverage on shares of Exact Sciences in a research note on Thursday, December 14th. They set a "buy" rating and a $90.00 target price on the stock. Citigroup reaffirmed a "buy" rating and issued a $100.00 target price on shares of Exact Sciences in a research report on Wednesday, April 3rd. Finally, William Blair reiterated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 22nd. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Exact Sciences has an average rating of "Moderate Buy" and an average target price of $97.44.

Exact Sciences Stock Down 0.9 %

EXAS traded down $0.66 during midday trading on Wednesday, hitting $73.60. 2,296,939 shares of the company's stock traded hands, compared to its average volume of 2,252,122. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.32 and a quick ratio of 2.07. The company has a market cap of $13.36 billion, a PE ratio of -64.56 and a beta of 1.25. The stock's fifty day simple moving average is $62.95 and its 200-day simple moving average is $65.12. Exact Sciences Co. has a one year low of $56.05 and a one year high of $100.77.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.26. The business had revenue of $646.89 million for the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. Exact Sciences's revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.72) EPS. As a group, equities analysts anticipate that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In other news, EVP Sarah Condella sold 2,000 shares of the stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the transaction, the executive vice president now owns 73,787 shares of the company's stock, valued at approximately $5,165,090. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Sarah Condella sold 2,000 shares of the company's stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the completion of the sale, the executive vice president now directly owns 73,787 shares of the company's stock, valued at approximately $5,165,090. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin T. Conroy sold 14,791 shares of Exact Sciences stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $908,611.13. Following the completion of the transaction, the chief executive officer now owns 1,224,357 shares in the company, valued at approximately $75,212,250.51. The disclosure for this sale can be found here. Insiders have sold a total of 69,113 shares of company stock worth $4,165,273 over the last three months. Corporate insiders own 1.30% of the company's stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.